Matrix metalloproteinases as new targets in Alzheimer's disease: Opportunities and Challenges
Pauline Zipfel (CERMN), Christophe Rochais (CERMN), K\'evin Baranger, (INP), Santiago Rivera (INP), Patrick Dallemagne (CERMN)
TL;DR
This paper reviews the dual roles of matrix metalloproteinases in physiological and pathological processes, emphasizing their potential as therapeutic targets in Alzheimer's disease and discussing recent advances and challenges in this area.
Contribution
It provides a comprehensive overview of MMPs' involvement in Alzheimer's disease and discusses new opportunities and challenges in targeting MMPs for therapy.
Findings
MMPs are implicated in Alzheimer's disease pathology.
Modulating MMP activity offers potential therapeutic benefits.
Challenges remain in developing specific MMP-targeted treatments.
Abstract
Although matrix metalloproteinases (MMPs) are implicated in the regulation of numerous physiological processes, evidences of their pathological roles have also been obtained in the last decades, making MMPs attractive therapeutic targets for several diseases. Recent discoveries of their involvement in central nervous system (CNS) disorders, and in particular in Alzheimer's disease (AD), have paved the way to consider MMP modulators as promising therapeutic strategies. Over the past few decades, diverse approaches have been undertaken in the design of
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.